Sight Sciences (NASDAQ:SGHT) CFO James Rodberg Sells 7,208 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 7,208 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $63,790.80. Following the completion of the sale, the chief financial officer directly owned 216,829 shares of the company’s stock, valued at approximately $1,918,936.65. This trade represents a 3.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT traded up $0.39 during mid-day trading on Monday, hitting $8.92. The company had a trading volume of 564,937 shares, compared to its average volume of 271,241. Sight Sciences, Inc. has a 12 month low of $3.19 and a 12 month high of $9.71. The firm has a market cap of $491.40 million, a P/E ratio of -15.93 and a beta of 2.45. The business’s 50-day simple moving average is $7.86 and its 200-day simple moving average is $5.76. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.95 and a quick ratio of 4.67.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.10. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%.The firm had revenue of $23.39 million during the quarter, compared to analysts’ expectations of $21.72 million. As a group, analysts predict that Sight Sciences, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC boosted its position in Sight Sciences by 21.6% during the 2nd quarter. Hsbc Holdings PLC now owns 46,707 shares of the company’s stock worth $255,000 after acquiring an additional 8,297 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Sight Sciences during the 2nd quarter worth about $520,000. Canada Pension Plan Investment Board bought a new position in shares of Sight Sciences in the 2nd quarter valued at about $299,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sight Sciences in the second quarter valued at about $60,000. Finally, Algert Global LLC increased its position in shares of Sight Sciences by 25.3% in the second quarter. Algert Global LLC now owns 28,266 shares of the company’s stock valued at $153,000 after acquiring an additional 5,706 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SGHT shares. Citigroup reissued a “neutral” rating on shares of Sight Sciences in a report on Monday. UBS Group raised their price objective on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen raised shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Sight Sciences has an average rating of “Moderate Buy” and an average target price of $7.88.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical technology company focused on developing and commercializing treatments for ophthalmic diseases. The company designs devices intended to address underlying causes of conditions such as glaucoma and dry eye disease, with an emphasis on less invasive procedures that can be performed in clinical settings.

Its product portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to perform canaloplasty and trabeculotomy procedures.